Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Gastroenterology ; 159(1): 81-95, 2020 07.
Article in English | MEDLINE | ID: mdl-32251668

ABSTRACT

BACKGROUND & AIMS: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has been characterized by fever, respiratory, and gastrointestinal symptoms as well as shedding of virus RNA into feces. We performed a systematic review and meta-analysis of published gastrointestinal symptoms and detection of virus in stool and also summarized data from a cohort of patients with COVID-19 in Hong Kong. METHODS: We collected data from the cohort of patients with COVID-19 in Hong Kong (N = 59; diagnosis from February 2 through February 29, 2020),and searched PubMed, Embase, Cochrane, and 3 Chinese databases through March 11, 2020, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We analyzed pooled data on the prevalence of overall and individual gastrointestinal symptoms (loss of appetite, nausea, vomiting, diarrhea, and abdominal pain or discomfort) using a random effects model. RESULTS: Among the 59 patients with COVID-19 in Hong Kong, 15 patients (25.4%) had gastrointestinal symptoms, and 9 patients (15.3%) had stool that tested positive for virus RNA. Stool viral RNA was detected in 38.5% and 8.7% among those with and without diarrhea, respectively (P = .02). The median fecal viral load was 5.1 log10 copies per milliliter in patients with diarrhea vs 3.9 log10 copies per milliliter in patients without diarrhea (P = .06). In a meta-analysis of 60 studies comprising 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6% (95% confidence interval [CI], 12.3-24.5); 11.8% of patients with nonsevere COVID-19 had gastrointestinal symptoms (95% CI, 4.1-29.1), and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms (95% CI, 6.9-36.7). In the meta-analysis, the pooled prevalence of stool samples that were positive for virus RNA was 48.1% (95% CI, 38.3-57.9); of these samples, 70.3% of those collected after loss of virus from respiratory specimens tested positive for the virus (95% CI, 49.6-85.1). CONCLUSIONS: In an analysis of data from the Hong Kong cohort of patients with COVID-19 and a meta-analysis of findings from publications, we found that 17.6% of patients with COVID-19 had gastrointestinal symptoms. Virus RNA was detected in stool samples from 48.1% patients, even in stool collected after respiratory samples had negative test results. Health care workers should therefore exercise caution in collecting fecal samples or performing endoscopic procedures in patients with COVID-19, even during patient recovery.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/prevention & control , Diarrhea/virology , Feces/virology , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Viral Load , Betacoronavirus/genetics , Betacoronavirus/pathogenicity , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Diarrhea/diagnosis , Diarrhea/epidemiology , Endoscopy, Gastrointestinal/standards , Gastrointestinal Tract/diagnostic imaging , Gastrointestinal Tract/virology , Hong Kong/epidemiology , Humans , Infection Control/standards , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Prevalence , RNA, Viral/isolation & purification , SARS-CoV-2
2.
Clin Infect Dis ; 69(7): 1232-1234, 2019 09 13.
Article in English | MEDLINE | ID: mdl-30721938

ABSTRACT

Sentinel hospital surveillance was instituted in Australia to detect the presence of pandemic group A Streptococcus strains causing scarlet fever. Genomic and phylogenetic analyses indicated the presence of an Australian GAS emm12 scarlet fever isolate related to United Kingdom outbreak strains. National surveillance to monitor this pandemic is recommended.


Subject(s)
Scarlet Fever/epidemiology , Scarlet Fever/microbiology , Streptococcus pyogenes/classification , Streptococcus pyogenes/genetics , Australia/epidemiology , Computational Biology/methods , Disease Outbreaks , Genome, Bacterial , Genomics/methods , Humans , Phylogeny , Population Surveillance , Scarlet Fever/diagnosis
3.
Transfusion ; 50(9): 1967-71, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20412524

ABSTRACT

BACKGROUND: To ensure a good preparedness for pandemic influenza A (H1N1), a study was conducted to investigate clinical effectiveness of hyperimmune intravenous globulin (H-IVIG) prepared from convalescent plasma donated by recovered patients. This article reports on the outcome of the collection phase of the study. STUDY DESIGN AND METHODS: Starting on August 26, 2009, all confirmed patients aged between 18 and 55 years were invited for participation into the study and screen for plasma donation eligibility. Effective September 17, 2009, those who were unwilling to consider screening for plasma were asked to donate whole blood. Plasma collected or separated from whole blood had to demonstrate sufficient neutralization antibodies titers of 40 or more before being channeled for H-IVIG production. RESULTS: By October 31, 2009, a total of 9101 persons were successfully contacted. A total of 1309 screening and 619 whole blood donation appointments were made. In the former 786 (60.0%) attended screening but only 301 could donate plasma by apheresis because of failure to meet blood donation eligibility criteria, failed laboratory tests, insufficient neutralization antibody titers, and inability to make the apheresis appointment. For those who opted for whole blood donation, 379 (61.2%) had attended and donated. A total of 276 L of convalescent plasma with sufficient neutralization antibodies titers was collected for H-IVIG production. DISCUSSION: The study highlighted a number of practical limitations in convalescent plasma collection programs and plasmapheresis is always the preferred mode of collection. It provided valuable learning experience for the blood transfusion service in future planning when large-scale collection is required.


Subject(s)
Blood Donors/statistics & numerical data , Immunoglobulins/immunology , Immunoglobulins/isolation & purification , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Plasma/immunology , Adolescent , Adult , Female , Humans , Immunoglobulins/therapeutic use , Influenza, Human/immunology , Male , Middle Aged , Young Adult
4.
FEBS Lett ; 580(10): 2414-20, 2006 May 01.
Article in English | MEDLINE | ID: mdl-16638566

ABSTRACT

SARS-associated coronavirus was identified as the etiological agent of severe acute respiratory syndrome and a large virus pool was identified in wild animals. Virus generates drug resistance through fast mutagenesis and escapes antiviral treatment. siRNAs targeting different genes would be an alternative for overcoming drug resistance. Here, we report effective siRNAs targeting structural genes (i.e., spike, envelope, membrane, and nucleocapsid) and their antiviral kinetics. We also showed the synergistic effects of two siRNAs targeting different functional genes at a very low dose. Our findings may pave a way to develop cost effective siRNA agents for antiviral therapy in the future.


Subject(s)
RNA, Small Interfering , Severe acute respiratory syndrome-related coronavirus/genetics , Viral Proteins/genetics , Animals , Base Sequence , Cells, Cultured , Cytopathogenic Effect, Viral , DNA Primers , Kinetics , Macaca mulatta , Reverse Transcriptase Polymerase Chain Reaction , Severe acute respiratory syndrome-related coronavirus/enzymology , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Severe acute respiratory syndrome-related coronavirus/physiology , Virus Replication
5.
Clin Chem ; 52(2): 303-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16339303

ABSTRACT

BACKGROUND: Malaria is one of the most important parasitic infections in humans. A sensitive diagnostic test for malaria that could be applied at the community level could be useful in programs to control the disease. The aim of the present work was to develop a simple, inexpensive molecular test for Plasmodium falciparum. METHODS: Blood was collected from controls (n = 100) and from patients diagnosed with falciparum malaria infection (n = 102), who were recruited to the study. Heat-treated blood samples were tested by a loop-mediated isothermal amplification (LAMP) assay for P. falciparum. Results were interpreted by a turbidity meter in real time or visually at the end of the assay. To evaluate the assay, DNA from these samples was purified and tested by PCR. Results from the LAMP and PCR assays were compared. RESULTS: The LAMP assay detected P. falciparum directly from heat-treated blood. The quantitative data from the assay correlated to the parasite counts obtained by blood-film microscopic analyses. When we used the PCR assay as the comparison method, the sensitivity and specificity of the LAMP assay were 95% and 99%, respectively. CONCLUSIONS: Unlike PCR, the LAMP assay does not require purified DNA for efficient DNA amplification, thereby reducing the cost and turnaround time for P. falciparum diagnosis. The assay requires only basic instruments, and assay positivity can be verified by visual inspection.


Subject(s)
DNA, Protozoan/blood , Hot Temperature , Malaria, Falciparum/diagnosis , Plasmodium falciparum/isolation & purification , Polymerase Chain Reaction , Specimen Handling/methods , Animals , Base Sequence , Calibration , DNA, Protozoan/genetics , Humans , Malaria, Falciparum/blood , Molecular Sequence Data , Plasmodium falciparum/genetics , Polymerase Chain Reaction/economics , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/standards , Sensitivity and Specificity
6.
J Clin Microbiol ; 43(7): 3457-9, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16000477

ABSTRACT

We compared the performance of a recently established real-time loop-mediated amplification (LAMP) assay with the one from a highly sensitive quantitative PCR assay. None of these assays produced false-positive results in this study. For samples isolated from patients within the first 3 days of disease onset, the detection rate of the quantitative PCR assay was higher (14 of 15 were positive) than the LAMP assay (9 of 15 were positive). By contrast, the detection rates of these assays toward specimens sampled from patients with more than 3 days of illness were similar (32 of 44 for PCR and 33 of 44 for LAMP were positive). The simpler operation of LAMP might be a possible solution for on-site diagnosis.


Subject(s)
Nucleic Acid Amplification Techniques/methods , Reverse Transcriptase Polymerase Chain Reaction/methods , Severe Acute Respiratory Syndrome/diagnosis , Severe Acute Respiratory Syndrome/virology , Severe acute respiratory syndrome-related coronavirus/isolation & purification , Humans , Nasopharynx/virology , Reproducibility of Results , Severe acute respiratory syndrome-related coronavirus/genetics , Sensitivity and Specificity
7.
J Med Virol ; 76(4): 435-40, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15977248

ABSTRACT

Four clinical isolates of SARS coronavirus were serially passaged in two primate cell lines (FRhK4 and Vero E6). Viral genetic sequences encoding for structural proteins and open reading frames 6--8 were determined in the original clinical specimen, the initial virus isolate (passage 0) and at passages 5, 10, and 15. After 15 passages, a total of 15 different mutations were identified and 12 of them were non-synonymous mutations. Seven of these mutations were recurrent mutation and all located at the spike, membrane, and Orf 8a protein encoding sequences. Mutations in the membrane protein and a deletion in ORF 6--8 were already observed in passage 0, suggesting these amino acid substitutions are important in the adaptation of the virus isolate in primate cell culture. A mutation in the spike gene (residue 24079) appeared to be unique to adaptation in FRhK4 cells. It is important to be aware of cell culture associated mutations when interpreting data on molecular evolution of SARS coronavirus.


Subject(s)
Mutation , Severe acute respiratory syndrome-related coronavirus/genetics , Adaptation, Biological , Amino Acid Substitution , Animals , Cell Line , Coronavirus M Proteins , Coronavirus Nucleocapsid Proteins , DNA, Viral/chemistry , DNA, Viral/genetics , Haplorhini , Membrane Glycoproteins/genetics , Nucleocapsid Proteins/genetics , Open Reading Frames , Polymerase Chain Reaction , Severe acute respiratory syndrome-related coronavirus/growth & development , Severe acute respiratory syndrome-related coronavirus/isolation & purification , Sequence Analysis, DNA , Serial Passage , Severe Acute Respiratory Syndrome/virology , Spike Glycoprotein, Coronavirus , Viral Envelope Proteins/genetics , Viral Matrix Proteins/genetics , Viroporin Proteins
8.
J Clin Microbiol ; 43(1): 427-30, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15635005

ABSTRACT

Here we describe the use of the loop-mediated isothermal amplification (LAMP) method to detect human influenza viruses (H1 to H3). Our results were correlated 100% with results deduced from routine clinical diagnostic tests. In addition, we also developed a LAMP assay specific for human beta-actin cDNA as a quality control test.


Subject(s)
Influenza A virus/isolation & purification , Nucleic Acid Amplification Techniques/methods , Actins/genetics , DNA Primers , DNA, Complementary/analysis , DNA, Viral/analysis , Humans , Influenza A virus/genetics , Influenza, Human/virology , Sensitivity and Specificity
9.
BMC Infect Dis ; 4(1): 57, 2004 Dec 09.
Article in English | MEDLINE | ID: mdl-15588295

ABSTRACT

BACKGROUND: Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical presentation of PCP in immunosuppressed patients have been well-reported in the literature. However, the clinical importance of PCP manifesting in the setting of an immunorestitution disease (IRD), defined as an acute symptomatic or paradoxical deterioration of a (presumably) preexisting infection, which is temporally related to the recovery of the immune system and is due to immunopathological damage associated with the reversal of immunosuppressive processes, has received relatively little attention until recently. CASE PRESENTATION: We aim to better define this unique clinical syndrome by reporting two cases of PCP manifesting acutely with respiratory failure during reversal of immunosuppression in non-HIV infected patients, and reviewed the relevant literature. We searched our databases for PCP cases manifesting in the context of IRD according to our predefined case definition, and reviewed the case notes retrospectively. A comprehensive search was performed using the Medline database of the National Library of Medicine for similar cases reported previously in the English literature in October 2003. A total of 28 non-HIV (excluding our present case) and 13 HIV-positive patients with PCP manifesting as immunorestitution disease (IRD) have been reported previously in the literature. During immunorestitution, a consistent rise in the median CD4 lymphocyte count (28/microL to 125/microL), with a concomitant fall in the median HIV viral load (5.5 log10 copies/ml to 3.1 log10 copies/ml) was observed in HIV-positive patients who developed PCP. A similar upsurge in peripheral lymphocyte count was observed in our patients preceding the development of PCP, as well as in other non-HIV immunosuppressed patients reported in the literature. CONCLUSIONS: PCP manifesting as IRD may be more common than is generally appreciated. Serial monitoring of total lymphocyte or CD4 count could serve as a useful adjunct to facilitate the early diagnosis and pre-emptive treatment of this condition in a wide range of immunosuppressed hosts, especially in the presence of new pulmonary symptoms and/or radiographic abnormalities compatible with the diagnosis.


Subject(s)
Immunosuppression Therapy , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/diagnosis , Adult , Antifungal Agents/therapeutic use , CD4 Lymphocyte Count , Female , HIV Infections , Humans , Immunocompromised Host , Immunosuppression Therapy/adverse effects , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Opportunistic Infections , Pneumonia, Pneumocystis/drug therapy
10.
Emerg Infect Dis ; 10(2): 294-9, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15030700

ABSTRACT

Cases of severe acute respiratory syndrome (SARS) were investigated for SARS coronavirus (SARS-CoV) through RNA tests, serologic response, and viral culture. Of 537 specimens from patients in whom SARS was clinically diagnosed, 332 (60%) had SARS-CoV RNA in one or more clinical specimens, compared with 1 (0.3%) of 332 samples from controls. Of 417 patients with clinical SARS from whom paired serum samples were available, 92% had an antibody response. Rates of viral RNA positivity increased progressively and peaked at day 11 after onset of illness. Although viral RNA remained detectable in respiratory secretions and stool and urine specimens for >30 days in some patients, virus could not be cultured after week 3 of illness. Nasopharyngeal aspirates, throat swabs, or sputum samples were the most useful clinical specimens in the first 5 days of illness, but later in the illness viral RNA could be detected more readily in stool specimens.


Subject(s)
Severe Acute Respiratory Syndrome/diagnosis , Severe Acute Respiratory Syndrome/virology , Severe acute respiratory syndrome-related coronavirus/isolation & purification , Antibodies, Viral/blood , Humans , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , Severe acute respiratory syndrome-related coronavirus/genetics , Severe Acute Respiratory Syndrome/immunology , Time Factors
13.
Gastroenterology ; 125(4): 1011-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14517783

ABSTRACT

BACKGROUND AND AIMS: Severe acute respiratory syndrome (SARS) is a recently emerged infection from a novel coronavirus (CoV). Apart from fever and respiratory complications, gastrointestinal symptoms are frequently observed in patients with SARS but the significance remains undetermined. Herein, we describe the clinical, pathologic, and virologic features of the intestinal involvement of this new viral infection. METHODS: A retrospective analysis of the gastrointestinal symptoms and other clinical parameters of the first 138 patients with confirmed SARS admitted for a major outbreak in Hong Kong in March 2003 was performed. Intestinal specimens were obtained by colonoscopy or postmortem examination to detect the presence of coronavirus by electron microscopy, virus culture, and reverse-transcription polymerase chain reaction. RESULTS: Among these 138 patients with SARS, 28 (20.3%) presented with watery diarrhea and up to 38.4% of patients had symptoms of diarrhea during the course of illness. Diarrhea was more frequently observed during the first week of illness. The mean number of days with diarrhea was 3.7 +/- 2.7, and most diarrhea was self-limiting. Intestinal biopsy specimens obtained by colonoscopy or autopsy showed minimal architectural disruption but the presence of active viral replication within both the small and large intestine. Coronavirus was also isolated by culture from these specimens, and SARS-CoV RNA can be detected in the stool of patients for more than 10 weeks after symptom onset. CONCLUSIONS: Diarrhea is a common presenting symptom of SARS. The intestinal tropism of the SARS-CoV has major implications on clinical presentation and viral transmission.


Subject(s)
Diarrhea/virology , Enteritis/virology , Severe Acute Respiratory Syndrome/complications , Severe acute respiratory syndrome-related coronavirus/isolation & purification , Adult , Colonoscopy , Diarrhea/pathology , Enteritis/pathology , Feces/virology , Female , Hong Kong , Humans , Male , Middle Aged , RNA, Viral/analysis , Retrospective Studies , Severe acute respiratory syndrome-related coronavirus/genetics , Severe Acute Respiratory Syndrome/pathology
14.
Lancet ; 361(9371): 1773-8, 2003 May 24.
Article in English | MEDLINE | ID: mdl-12781536

ABSTRACT

BACKGROUND: Severe acute respiratory syndrome (SARS) is a novel infectious disease with global impact. A virus from the family Coronaviridae has been identified as the cause, but the pathogenesis is still unclear. METHODS: Post-mortem tissue samples from six patients who died from SARS in February and March, 2003, and an open lung biopsy from one of these patients were studied by histology and virology. Only one full autopsy was done. Evidence of infection with the SARS-associated coronavirus (SARS-CoV) and human metapneumovirus was sought by reverse-transcriptase PCR and serology. Pathological samples were examined by light and electron microscopy and immunohistochemistry. FINDINGS: All six patients had serological evidence of recent infection with SARS-CoV. Diffuse alveolar damage was common but not universal. Morphological changes identified were bronchial epithelial denudation, loss of cilia, and squamous metaplasia. Secondary bacterial pneumonia was present in one case. A giant-cell infiltrate was seen in four patients, with a pronounced increase in macrophages in the alveoli and the interstitium of the lung. Haemophagocytosis was present in two patients. The alveolar pneumocytes also showed cytomegaly with granular amphophilic cytoplasm. The patient for whom full autopsy was done had atrophy of the white pulp of the spleen. Electron microscopy revealed viral particles in the cytoplasm of epithelial cells corresponding to coronavirus. INTERPRETATION: SARS is associated with epithelial-cell proliferation and an increase in macrophages in the lung. The presence of haemophagocytosis supports the contention that cytokine dysregulation may account, at least partly, for the severity of the clinical disease. The case definition of SARS should acknowledge the range of lung pathology associated with this disease.


Subject(s)
Lung/pathology , Severe Acute Respiratory Syndrome/pathology , Adult , Biopsy , Bronchi/pathology , Cell Nucleus/ultrastructure , Fatal Outcome , Female , Giant Cells/ultrastructure , Humans , Lung/virology , Male , Metaplasia , Middle Aged , Organ Size , Severe acute respiratory syndrome-related coronavirus/isolation & purification , Severe Acute Respiratory Syndrome/complications , Severe Acute Respiratory Syndrome/virology
15.
N Engl J Med ; 348(20): 1977-85, 2003 May 15.
Article in English | MEDLINE | ID: mdl-12671062

ABSTRACT

BACKGROUND: Information on the clinical features of the severe acute respiratory syndrome (SARS) will be of value to physicians caring for patients suspected of having this disorder. METHODS: We abstracted data on the clinical presentation and course of disease in 10 epidemiologically linked Chinese patients (5 men and 5 women 38 to 72 years old) in whom SARS was diagnosed between February 22, 2003, and March 22, 2003, at our hospitals in Hong Kong, China. RESULTS: Exposure between the source patient and subsequent patients ranged from minimal to that between patient and health care provider. The incubation period ranged from 2 to 11 days. All patients presented with fever (temperature, >38 degrees C for over 24 hours), and most presented with rigor, dry cough, dyspnea, malaise, headache, and hypoxemia. Physical examination of the chest revealed crackles and percussion dullness. Lymphopenia was observed in nine patients, and most patients had mildly elevated aminotransferase levels but normal serum creatinine levels. Serial chest radiographs showed progressive air-space disease. Two patients died of progressive respiratory failure; histologic analysis of their lungs showed diffuse alveolar damage. There was no evidence of infection by Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella pneumophila. All patients received corticosteroid and ribavirin therapy a mean (+/-SD) of 9.6+/-5.42 days after the onset of symptoms, and eight were treated earlier with a combination of beta-lactams and macrolide for 4+/-1.9 days, with no clinical or radiologic efficacy. CONCLUSIONS: SARS appears to be infectious in origin. Fever followed by rapidly progressive respiratory compromise is the key complex of signs and symptoms from which the syndrome derives its name. The microbiologic origins of SARS remain unclear.


Subject(s)
Disease Outbreaks , Severe Acute Respiratory Syndrome/epidemiology , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Antiviral Agents/therapeutic use , Contact Tracing , Drug Therapy, Combination , Female , Hong Kong/epidemiology , Humans , Lung/diagnostic imaging , Male , Middle Aged , Radiography , Ribavirin/therapeutic use , Severe Acute Respiratory Syndrome/drug therapy , Severe Acute Respiratory Syndrome/microbiology , Severe Acute Respiratory Syndrome/transmission
SELECTION OF CITATIONS
SEARCH DETAIL
...